Table 1.
Patients’ characteristics of BRAF-BeCool population based on tumour sidedness.
| Right sided N = 179 | Left sided and rectum N = 116 | |||||
|---|---|---|---|---|---|---|
| Triplet+/−bev N = 72 n (%) | Doublet+/−bev N = 107 n (%) | p | Triplet+/−bev N = 52 n (%) | Doublet+/−bev N = 64 n (%) | p | |
| Age (years) | 0.002 | 0.23 | ||||
| Median | 59 | 64 | 59 | 61 | ||
| Range (min–max) | 27–74 | 28–74 | 34–74 | 24–75 | ||
| Sex | 0.84 | 0.80 | ||||
| Male | 30 (42%) | 43 (40%) | 28 (54%) | 36 (56%) | ||
| Female | 42 (58%) | 64 (60%) | 24 (46%) | 28 (44%) | ||
| ECOG-PS | 0.032 | 0.18 | ||||
| 0 | 60 (83%) | 74 (69%) | 40 (77%) | 42 (66%) | ||
| 1–2 | 12 (17%) | 33 (31%) | 12 (23%) | 22 (34%) | ||
| Microsatellite status | 0.32 | 0.0085 | ||||
| pMMR/MSS | 48 (81%) | 45 (74%) | 43 (100%) | 24 (83%) | ||
| dMMR/MSI-H | 11 (19%) | 16 (26%) | 0 (0%) | 5 (17%) | ||
| NA | 13 | 46 | 9 | 35 | ||
| Resected primary tumour | 0.69 | 0.71 | ||||
| Yes | 57 (79%) | 82 (77%) | 35 (67%) | 41 (64%) | ||
| No | 15 (21%) | 25 (23%) | 17 (33%) | 23 (36%) | ||
| Liver only disease | 0.093 | 0.49 | ||||
| Yes | 22 (31%) | 21 (20%) | 16 (31%) | 16 (25%) | ||
| No | 50 (69%) | 86 (80%) | 36 (69%) | 48 (75%) | ||
| Number of metastatic sites | 0.58 | 0.94 | ||||
| 1 | 38 (53%) | 52 (49%) | 24 (46%) | 30 (47%) | ||
| >1 | 34 (47%) | 55 (51%) | 28 (54%) | 34 (53%) | ||
| R0/R1 resection of metastases | 0.20 | 0.33 | ||||
| Yes | 17 (24%) | 17 (16%) | 7 (13%) | 13 (20%) | ||
| No | 55 (76%) | 90 (84%) | 45 (87%) | 51 (80%) | ||
| Time to metastases | 0.41 | 0.20 | ||||
| Synchronous | 68 (94%) | 96 (90%) | 47 (90%) | 52 (81%) | ||
| Metachronous | 4 (6%) | 11 (10%) | 5 (10%) | 12 (19%) | ||
| Semplified risk score | 0.30 | 0.68 | ||||
| High | 12 (17%) | 25 (24%) | 9 (17%) | 15 (24%) | ||
| Intermediate | 23 (32%) | 37 (36%) | 19 (37%) | 20 (31%) | ||
| Low | 37 (51%) | 42 (40%) | 24 (46%) | 29 (45%) | ||
| NA | – | 3 | – | – | ||
| Bevacizumab-based treatment | <0.001 | 0.0078 | ||||
| Yes | 70 (97%) | 72 (67%) | 48 (92%) | 46 (72%) | ||
| No | 2 (3%) | 35 (33%) | 4 (8%) | 18 (28%) | ||
Bold values indicate statistical significance p < 0.05.
Simplified score as described by Loupakis et al. [12].
N number, ECOG-PS Eastern Cooperative Oncology Group Performance Status, NA not available, pMMR proficient mismatched repair, MSS microsatellite stable, dMMR deficient mismatched repair, MSI-H microsatellite instability high.